Eye Blink Rate and Putamen DaTScan Covariation in Parkinson’s Disease
Objective: To examine the relationship between blink rate and DaTScan in Parkinson’s disease. Background: Spontaneous eye-blink rate (BR) is blinking without external triggers. Parkinson's disease…Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis
Objective: The study aims to apply S-ICA to 18F-fluorodeoxyglucose (FDG) data in progressive supranuclear palsy (PSP) patients, identifing PSP-specific independent metabolic covariate networks. We also…Putaminal dopamine modulates movement motivation in Parkinson’s disease
Objective: To investigate the quantitative effect of dopamine depletion on the motivation of motor effort in Parkinson’s disease. Background: The relative inability to produce effortful…Dopaminergic alterations in patients with Alzheimer’s disease
Objective: The objective of this study was to conduct a meta-analysis to determine the pooled mean difference (MD) in dopaminergic measures between Alzheimer’s disease and…Criteria Defining Chronic Pain Associated with Parkinson Disease
Objective: To assess the factors defining the association of chronic pain (>3 months) with PD. Background: Non-motor symptoms can be often associated with Parkinson disease…Anodal transcranial direct current stimulation could change the metabolomic profiles of cerebrospinal fluid in Parkinson’s disease
Objective: We tried to identify meaningful metabolite change after anodal tDCS in clinically diagnosed PD patients by adopting metabolomic analysis Background: Transcranial direct current stimulation…Long duration response to levodopa in advanced Parkinson disease
Objective: In patients with advanced Parkinson disease, it is possible to obtain a response to duodopa, if the dose is adjusted appropriately, even taking periods…The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
Objective: To investigate whether NLX-112, a potent and selective 5-HT1A agonist is neuroprotective in a mouse MPTP model of Parkinson’s Disease (PD) [1]. Background: There…Levodopa Carbidopa Intestinal Gel for Parkinson’s Disease over 11 years: A Single Center “Real-World” Experience
Objective: To review long-term real-world experience and clinical outcomes in PD patients with LCIG therapy over 11 years in a multidisciplinary University clinic setting. Background:…Ventral tegmental deep brain stimulation does not influence risk-taking behaviour in a standard gambling task
Objective: We here used a standard gambling task that involved risky decision-making. This permitted us to measure the effects of ventral tegmental area (VTA) deep…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 26
- Next Page »